Immunogenicity and safety of monovalent P1.7h,4 meningococcal outer membrane vesicle vaccine in toddlers: Comparison of two vaccination schedules and two vaccine formulations

Vaccine

Volumn 19, Issue 9-10, 2000, Pages 1141-1148

  De Kleijn, Ester D ^a   De Groot, Ronald ^a   Lafeber, Arianne B ^b   Labadie, Jerry ^b   Van Limpt, Kees C J P ^b   Visser, John ^a   Berbers, Guy A M ^b   Van Alphen, Loek ^b   Rümke, Hans C ^b  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Children; Neisseria meningitidis; Outer membrane vesicle vaccine

Indexed keywords

MENINGOCOCCUS VACCINE; OLIGOSACCHARIDE; OUTER MEMBRANE PROTEIN;

ADSORPTION; ANTIBACTERIAL ACTIVITY; ARTICLE; CHILD; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERANCE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MEMBRANE VESICLE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NETHERLANDS; OUTER MEMBRANE; PRIORITY JOURNAL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; BLOOD BACTERICIDAL ACTIVITY; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION; IMMUNIZATION SCHEDULE; MALE; MENINGOCOCCAL VACCINES;

EID: 0034623975     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00320-0     Document Type: Article

References (25)

1. Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: A brief survey
2. Serum antibodies to cross-reactive Neisseria outer membrane antigens in healthy persons and patients with meningococcal disease
3. Human immune response to meningococcal outer membrane protein epitopes after natural infection or vaccination
4. Immune responses of infants and children to disseminated infections with Neisseria meningitidis
5. Dynamics of carriage of Neisseria meningitidis in a group of military recruits
6. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil
7. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway
8. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease
9. Effecacy evaluation of the Cuban vaccine VA-MENGOC-BC against disease caused by serogroup B Neisseria meningitidis
10. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine
11. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine
12. Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein
13. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine
14. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: A randomized controlled trial in Chile
15. Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease
16. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine
17. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins
18. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children 2-3 and 7-8 years of age
19. Human immunity to the meningococcus. I. The role of humoral antibodies
20. Human immunity to the meningococcus. II. Development of natural immunity
21. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: Comparison with efficacy
22. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4
23. Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent outer membrane vesicle vaccine
24. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland